Valuation: Guided Therapeutics Inc

Market Cap 24.13M 20.91M 19.74M 17.9M 33.59M 2.31B 33.83M 236M 90.82M 1.17B 90.65M 88.65M 3.73B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 27.01M 23.4M 22.09M 20.04M 37.59M 2.59B 37.86M 264M 102M 1.31B 101M 99.21M 4.18B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
09-09 Guided Therapeutics, Inc. and Türkiye Ministry of Health Reach Collaborative Agreement for Primary Screening Test for Cervical Cancer CI
08-13 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-14 Guided Therapeutics, Inc. Announces New Agreement With Yuanshuo Medical Instruments Corporation CI
06-16 Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA CI
05-15 Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-30 Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
12-17 Guided Therapeutics, Inc. Announces Preliminary Findings from Its FDA Pivotal Clinical Trial CI
12-11 Guided Therapeutics, Inc. Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor CI
11-19 Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation CI
11-13 Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-19 Guided Therapeutics, Inc. Receives $70,000 from New Chinese Distribution Partner That Provides Products for 2 Million Annual Cervical Cancer Screenings CI
25-08-14 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
Manager TitleAgeSince
Chief Executive Officer 70 2023-03-05
Chief Tech/Sci/R&D Officer 70 2010-12-01
Director TitleAgeSince
Director/Board Member 70 2016-11-30
Director/Board Member 76 2006-04-09
Chairman 67 2013-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%-0.03%+27.98%+19.00% 227B
+1.55%-2.12%+6.95%-19.82% 143B
+2.38%+3.07%-15.95%+24.43% 134B
+4.82%-5.75%-56.14%-14.87% 65.29B
-0.17%-0.31%-18.68%-15.72% 50.09B
+1.36%-4.87%+10.25%+15.54% 49.29B
-0.09%-2.69%+19.12%+27.79% 41.39B
+0.41%+0.15%+38.80%+50.73% 40.28B
+2.16%-2.35%-17.45%+51.04% 31.9B
Average +1.45%-1.73%-0.57%+15.35% 86.84B
Weighted average by Cap. +1.45%-0.91%+3.73%+10.97%

Financials

2024 2025
Net sales 7K 6.07K 5.72K 5.19K 9.74K 671K 9.81K 68.36K 26.34K 340K 26.29K 25.71K 1.08M 767K 665K 627K 569K 1.07M 73.51M 1.08M 7.49M 2.89M 37.29M 2.88M 2.82M 119M
Net income -2.42M -2.09M -1.98M -1.79M -3.36M -232M -3.39M -23.6M -9.1M -118M -9.08M -8.88M -374M -3.2M -2.77M -2.61M -2.37M -4.45M -306M -4.48M -31.21M -12.03M -155M -12M -11.74M -494M
Net Debt 1.77M 1.53M 1.45M 1.31M 2.46M 170M 2.48M 17.3M 6.66M 86.11M 6.65M 6.51M 274M 2.88M 2.49M 2.35M 2.13M 4M 276M 4.03M 28.09M 10.82M 140M 10.8M 10.56M 445M
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!